Foamix Announces Phase II Clinical Trial of Topical Minocycline Foam for Rosacea

Foamix Receives US Patent for Oleaginous Foam

Foamix and BioMAS to Develop Novel Therapy for Genital Warts

Foamix to present at the UBS 2010 Global Specialty Pharmaceuticals Conference

New U.S. Patent Grant to Foamix for its Hygroscopic and Waterless Breakable Foam Technology

Foamix Receives a New U.S. Patent for its Emollient and Aqueous Foam Technology

Foamix is Granted a Fourth U.S. Patent for OilGel™, Directed to Pharmaceutical Compositions and their Dermatological, Gynecological and Ophthalmic Applications

Foamix Ltd. and Therapeutics Inc. Enter into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases

US Grant for Foamix's Saccharide Foam Patent - Topical "Sweet Foam" Products for Wound & Burn Therapy

Foamix is a Finalist for the Red Herring 100 Global Award for Most Promising Technology Ventures

Dermatology co Foamix teams with Switzerland's Galderma

Foamix Expands International Patent Protection for its Emollient Foam Platform

Foamix Extends Collaboration with Galderma

Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis

Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis

Foamix is Finalist for International 2008 SCRIP Award

Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis

Omnibus Survey:72% of Women Are Dissatisfied with Their Current Treament of Vaginal Infection

Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases

Foamix is a finalist for the Red Herring 100 Europe 2008 Award

BIRD invests $14m in 16 joint projects; English Hebrew

Foamix Announces New Foam Patent Approvals

Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis

Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology

In-Pharma Technologist.com: Best Foam Forward

Foamix presents Innovative Intra-Vaginal Foam Delivery for Gynecology

Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam

YNET: Collaboration with Warner Chilcott on gynecologic treatment (article in Hebrew)

Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product

Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam

Globes: Foamix collaborates with Warner Chilcott on acne treatment

Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne


 

Foamix has a strong in-house pipeline of dermatological and gynecological drugs. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies, addressing major unmet needs in dermatology, gynecology and ophthalmic therapy. In the future the company intends to expedite its innovative drug development programs towards Phase III studies and drug approvals.

To date, Foamix has 30 issued patents worldwide, including 9 US patents as well as >150 pending applications worldwide.

Strategy


Foamix is an innovative leader in topical drug and cosmetic delivery, utilizing the proprietary Foamix Foam and OILGEL™ platforms. We focus on topical foam products for the prescription, OTC and cosmetics markets.

Our strategy is designed to maximize potential opportunities for our unique foam platforms:
  • We promote global development by forming strategic alliances and corporate partnerships with leading pharmaceutical companies. We will continue to form such alliances in order to accelerate product development and commercialization by joining forces with market leaders.
  • We continue to enhance our R&D capabilities and expand our project line. We are expanding our relations and network of collaborations with centers of excellence.
  • We continue to develop additional forms and versions of the Foamix Foam and OILGEL™ platforms, suitable for all forms of actives.
  • We actively prosecute our intellectual property portfolio to protect our franchise and our current and future collaborative developments.

Foamix utilizes its core technologies to develop products in-house which are available for licensing and also co-operates with leading pharmaceutical companies in the development of foam-based products for the delivery of proprietary actives.